Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.
|Original language||English (US)|
|Number of pages||2|
|Journal||Antimicrobial agents and chemotherapy|
|State||Published - Nov 2012|
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases